Payment overview · 2025
General Payments
$632.32
26 reported records · 11 companies
Healthcare provider profile · identity verified
Cale Li, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1134784762
Verified facts
What the public records show
CMS Open Payments records show Cale Li, MD received $632.32 in general payments during 2025 across 26 reported records.
ViiV Healthcare Company accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $150.99 | 23.9% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $150.47 | 23.8% | 9 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $117.80 | 18.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $59.60 | 9.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.56 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.80 | 3.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.37 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.41 | 3.2% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.03 | 3.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.98 | 3.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.31 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $543.32 | 25 |
| Education | $89.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $150.99 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $150.47 | 9 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $117.80 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $117.80 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $59.60 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 120 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 100 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
40 | 14 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
100 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
120 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 246 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 73 |
| Diclofenac Sodium | Diclofenac Sodium | 232 | 61 |
| Gabapentin | Gabapentin | 179 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 24 |
| Atorvastatin Calcium | Atorvastatin Calcium | 158 | 44 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 142 | 42 |
| Mirtazapine | Mirtazapine | 137 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 129 | 22 |
| Mounjaro | Tirzepatide | 127 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 42 |
| Jardiance | Empagliflozin | 120 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 31 |
| Kerendia | Finerenone | 100 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 94 | 26 |
| Montelukast Sodium | Montelukast Sodium | 84 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 16 |
| Omeprazole | Omeprazole | 82 | 24 |
| Famotidine | Famotidine | 79 | 15 |
| Furosemide | Furosemide | 77 | 28 |
| Tramadol Hcl | Tramadol Hcl | 75 | 17 |
| Silver Sulfadiazine | Silver Sulfadiazine | 66 | 25 |
| Metformin Hcl | Metformin Hcl | 65 | 21 |
| Clonazepam | Clonazepam | 61 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 18 |
| Ozempic | Semaglutide | 58 | 15 |
| Lactulose | Lactulose | 57 | 19 |
| Lidocaine | Lidocaine | 56 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 20 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 52 | 13 |
| Losartan Potassium | Losartan Potassium | 52 | 19 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Naproxen | Naproxen | 48 | 16 |
| Eliquis | Apixaban | 46 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | 14 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Levetiracetam | Levetiracetam | 44 | suppressed |
| Lisinopril | Lisinopril | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | 12 |
| Ssd | Silver Sulfadiazine | 44 | 13 |
| Carvedilol | Carvedilol | 43 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 43 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 41 | suppressed |
| Nifedipine Er | Nifedipine | 40 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 40 | 14 |
| Entresto | Sacubitril/Valsartan | 39 | 15 |
| Januvia | Sitagliptin Phosphate | 39 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 39 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Finasteride | Finasteride | 36 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 14 |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 27 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 22 | suppressed |
| Baclofen | Baclofen | 21 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $632.32 · 26 records | ViiV Healthcare Company | ACCRUFER, AIRSUPRA, APRETUDE, CAMZYOS, Cologuard Collection Kit, JARDIANCE, Kerendia, MOUNJARO, OPSUMIT, OTEZLA, REPATHA, TZIELD, UPTRAVI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error